References
- Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–62
- Bacon BR, Gordon SC, Lawitz E, et al. (2011). Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–17
- Chen L-Z, Rose P, Mao Y, et al. (2014). Mass balance and metabolite profiling of steady-state faldaprevir, a hepatitis C NS3/4 protease inhibitor, in healthy male subjects. Antimicrob Agents Chemother 58:2369–76
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–6
- Fried MW, Shiffman M, Reddy KR, et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–82
- Jacobson IM, McHutchison JG, Dusheiko G, et al. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–16
- Li Y, Zhou J, Ramsden D, et al. (2013). Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation. Drug Metab Dispos 42:384–93
- Llinàs-Brunet M, Bailey MD, Goudreau N, et al. (2010). Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335). J Med Chem 53:6466–76
- Manns MP, McHutchison JG, Gordon SC, et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958–65
- Nakano T, Lau GMG, Lau GML, et al. (2011). An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 32:339–45
- Poordad F, McCone J Jr, Bacon BR, et al. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–206
- Ramsden D, Tweedie DJ, Chan TS, et al. (2014). Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel co-cultured human hepatocyte system, Hepatopac™. Drug Metab Dispos 42:394–406
- Sabo J, Kashuba ADM, Ballow CH, et al. (2012). Cytochrome P450 interactions with the HCV protease inhibitor faldaprevir (BI 201335) in healthy volunteers. The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; Abstract A-1248
- Sulkowski MS, Asselah T, Lalezari J, et al. (2013a). Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 Trial. Hepatology 57:2143–54
- Sulkowski MS, Bourlière M, Bronowicki J-P, et al. (2013b). Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 Trial. Hepatology 57:2155–63
- White PW, Llinàs-Brunet M, Amad M, et al. (2010). Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4 protease. Antimicrob Agents Chemother 54:4611–18
- World Health Organization. (2012). Hepatitis C Fact Sheet N 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index.html [last accessed 23 Jan 2014]
- Zeuzem S, Andreone P, Pol S, et al. (2011). Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417–28